Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ALGS
#3397
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+1.30%
Variazione Mensile
-19.10%
Variazione di 6 mesi
-28.19%
Variazione Annuale
-28.19%
Chiusura Precedente
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
Volume
2
Mercati
Mercato Azionario Statunitense
Salute
ALGS
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
3.46 M
6.11 M
6.11 M
6.15 M
9.57 M
—
Valuation ratios
Enterprise value
25.74 M
—
—
—
—
—
Price to earnings ratio
-1.18
-1.9
-0.47
-0.54
-1.4
-4.32
Price to sales ratio
5.46
46.99
10.74
10.56
19.06
87.35
Price to cash flow ratio
0.46
3.09
0.71
0.72
1.07
5.58
Price to book ratio
0.14
8.61
0.22
0.2
0.28
9.32
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.1
-1.17
0.29
-0.12
-0.5
-1.5
Return on equity %
0.18
-2.84
0.37
-0.16
-0.76
-3.38
Return on invested capital %
-603
-678.92
-682.21
-671.41
-1 081.54
-3 114.08
Gross margin %
100
100
100
100
100
400
Operating margin %
-1 150.34
-2 269.65
-1 732.04
-1 360.22
-2 485.63
-7 847.54
EBITDA margin %
—
—
—
—
—
—
Net margin %
522.11
-9 067.33
3 878.31
-1 162.12
-4 788.69
-11.14 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.81
2.86
7.56
6.31
4.7
21.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.01
0.01
0.01
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-3.21
-2.94
-2.4
-1.65
-2.51
-9.49
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
11.97
9.08
15.83
13.07
10.2
48.19
Net current asset value per share
12.75
9.92
16.44
13.61
10.64
50.61
Tangible book value per share
8
-4.62
13.37
10.83
7.39
26.97
Working capital per share
9.41
6.45
14.27
11.45
8.38
40.55
Book value per share
8
-4.62
13.37
10.83
7.39
26.97
Notizie
Aligos Therapeutics mantiene rating Buy da H.C. Wainwright grazie ai progressi di pevifoscorvir
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Il titolo di Aligos Therapeutics sale grazie ai progressi dello studio HBV di Fase 2
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos Therapeutics nomina James Hassard come Chief Commercial Officer
Aligos therapeutics appoints James Hassard as chief commercial officer
Aligos Therapeutics: UBS avvia copertura con rating Buy sul pipeline di malattie epatiche
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos riporta effetto sinergico di perdita di peso con agonista THR-β
Aligos reports synergistic weight loss effect with THR-β agonist
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript